Safety evaluation of the mouse TCRα - transduced T cell product in preclinical models in vivo and in vitro
Adoptive cell therapy (ACT) based on TCR- or CAR-T cells has become an efficient immunotherapeutic approach for the treatment of various diseases, including cancer. Previously, we developed a novel strategy for generating therapeutic T cell products based on chain-centric TCRs, in which either α- or...
Guardado en:
Autores principales: | Anastasiia Kalinina, Alexandra Bruter, Nadezhda Persiyantseva, Yulia Silaeva, Maria Zamkova, Ludmila Khromykh, Dmitry Kazansky |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9a07af43c47d43499f688336181fc705 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation
por: Virginia Picanço-Castro, et al.
Publicado: (2021) -
A Framework to Identify Antigen-Expanded T Cell Receptor Clusters Within Complex Repertoires
por: Valentina Ceglia, et al.
Publicado: (2021) -
Epstein–Barr Virus+ B Cells in Breast Cancer Immune Response: A Case Report
por: Andrea Aran, et al.
Publicado: (2021) -
Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade V, et al.
Publicado: (2020) -
OPPORTUNITIES OF FLOW CYTOMETRY IN DIAGNOSTICS OF INFECTIOUS DISEASES. Part 2
por: S. V. Khaidukov, et al.
Publicado: (2014)